Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Phoebe Starr

Authored Items
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 in Breast Cancer, Immunotherapy
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Leukemia
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Emerging Therapies
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Breast Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
TON - September 2018, Vol 11, No 4 in Prostate Cancer
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 in Breast Cancer
Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Prostate Cancer
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Genitourinary Cancers
Immune Checkpoint Inhibitor plus VEGFR Inhibitor Combo Outperforms Sunitinib in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Renal-Cell Carcinoma
Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia
Phoebe Starr
Web Exclusives in Leukemia
A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?
Phoebe Starr
Web Exclusives in Lymphoma
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Lung Cancer
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Immunotherapy, Online First
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Breast Cancer
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Emerging Therapies
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Conference Correspondent
More Support for Regular Use of Low-Dose Aspirin
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Conference Correspondent
Cardiotoxicity with Targeted Therapies Is Rare, but Requires Attention
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Conference Correspondent
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Melanoma, Immunotherapy
Enzalutamide Safe for Patients at Increased Risk for Seizure
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Prostate Cancer
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in AACR News, Conference Correspondent
Survivorship Care Evolves with Fine-Tuning
Phoebe Starr
TON - July 2017, Vol 10, No 4 in Survivorship
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
Phoebe Starr
TON - July 2017, Vol 10, No 4 in Adverse Effects
Hormonal Therapy Associated with Anxiety in Men with Localized Prostate Cancer
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Genitourinary Cancers
New NCCN Distress Guidelines and Tools Encourage Patients to Speak Up
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Conference Correspondent, NCCN News
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Adverse Effects
Toxicities of Immunotherapy Require Awareness, Education
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Adverse Effects
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
Phoebe Starr
TOP - May 2017, Vol 10, No 2 in Adverse Effects
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
Phoebe Starr
TOP - May 2017, Vol 10, No 2 in Adverse Effects
Autologous Breast Reconstruction Has Better Outcomes Than Implants in Patients Receiving Radiotherapy
Phoebe Starr
TON - March 2017, Vol 10, No 2 in Breast Cancer
Specific Menopausal Symptoms Associated with Nonadherence to Hormonal Therapy in Women at Risk for Breast Cancer
Phoebe Starr
TON - March 2017, Vol 10, No 2 in Breast Cancer
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives in Conference Correspondent, In the News
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Web Exclusives in Conference Correspondent, In the News
Duloxetine Helps Reduce Aromatase Inhibitor–Associated Joint Pain
Phoebe Starr
TOP - February 2017, Vol 10, No 1 in Breast Cancer
Increased Attention to Cardiovascular Events in DLBCL Warranted
Phoebe Starr
TON - January 2017, Vol 10, No 1 in Conference Correspondent
Use Caution When Placing Catheters in Children with Cancer
Phoebe Starr
TON - January 2017, Vol 10, No 1 in Conference Correspondent
Call to Action: Address Patients’ Sexual Health
Phoebe Starr
TON - November 2016, Vol 9, No 6 in Supportive Care
Older Drugs in “New Clothes” Achieve Superior Outcomes
Phoebe Starr
TON - November 2016, Vol 9, No 6 in Hematologic Cancers
Older Drugs in “New Clothes” Achieve Superior Outcomes
Phoebe Starr
TOP - November 2016, Vol 9, No 4 in Hematologic Cancers
Aggressive End-of-Life Care Continues to Be Offered to Younger Patients with Cancer
Phoebe Starr
TON - September 2016, Vol 9, No 5 in Best Practices, Palliative Care
Price of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
TOP - August 2016, Vol 9, No 3 in Conference Correspondent
Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer
Phoebe Starr
TOP - May 2016, Vol 9, No 2 in Genitourinary Cancers
Aspirin Reduces Risk for Prostate Cancer Death
Phoebe Starr
TON March 2016 Vol 9 No 2 in Genitourinary Cancers
Docetaxel Does Not Compromise Long-Term QOL in Men with Metastatic Hormone-Sensitive Prostate Cancer
Phoebe Starr
TON March 2016 Vol 9 No 2 in Genitourinary Cancers
Active Holistic Surveillance Incorporates Diet, Supplements, Exercise for Low-Risk and Low-Intermediate–Risk Prostate Cancer
Phoebe Starr
TON March 2016 Vol 9 No 2 in Genitourinary Cancers
ABCs of Immunotherapy
Phoebe Starr
TOP November 2015 Vol 8 No 4 in Immunotherapy
Chemotherapy, Radiation Safe During Pregnancy in Second or Third Trimester
Phoebe Starr
TON November 2015 Vol 8 No 6 in Supportive Care
ABCs of Immunotherapy
Phoebe Starr
TON September 2015 Vol 8 No 5 in Online First
The State of Antibody-Drug Conjugates in 2015
Phoebe Starr
TON September 2015 Vol 8 No 5 in Drug Therapies
Being Single Raises Risks of Death for Patients with Cancer
Phoebe Starr
TON July 2015 Vol 8 No 4 in Supportive Care
No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
TON May 2015 Vol 8 No 3 in Genitourinary Cancers
AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer
Phoebe Starr
TON May 2015 Vol 8 No 3 in Genitourinary Cancers
ASSURE Trial: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
TOP - May 2015, Vol 8, No 2 in Genitourinary Cancers
Venetoclax Moves Forward in Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Hematologic Cancers
Novel Agent Effective for the Management of Cancer-Related Cachexia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Supportive Care
Posttransplant Brentuximab: New Standard of Care for Hodgkin Lymphoma?
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Hematologic Cancers
Novel Agent Effective for the Management of Cancer-Related Cachexia
Phoebe Starr
TON - January 2015 Vol 8 No 1 in Supportive Care
Potential New Approach to Treat Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 in Skin Cancer
Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 in Skin Cancer
Angiotensin System Inhibitors Extend Survival in Patients With Metastatic Renal Cell Carcinoma
Phoebe Starr
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
Phoebe Starr
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Role of Radiation and Imaging in DCIS Explained
Phoebe Starr
TON - January/February 2014 Vol 7 No 1 in Breast Cancer
Pazopanib: First Positive Maintenance Trial
Phoebe Starr
TON - December 2013 Vol 6 No 11 in Gynecologic Cancers
Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy
Phoebe Starr
TOP - May 2013, Vol 6, No 2 in Breast Cancer
Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy
Phoebe Starr
TON - March 2013, Vol 6, No 2 in Breast Cancer
Proton Beam Therapy: Similar Toxicity to Standard Radiation, at Much Higher Cost
Phoebe Starr
TOP - December 2012 VOL 5, NO 8 in Genitourinary Cancers
Last modified: December 21, 2012